Close
Leave blank for all. Otherwise, the first selected term will be the default instead of "Any".

BIO President and CEO Jim Greenwood to Chair BIO Ventures for Global Health Board of Directors

Jan 21 2016
BVGH engages leading biopharmaceutical companies in partnerships and programs to address challenging global health issues

BIO Applauds Move to Advance Senate Innovation Initiative Legislation

Jan 21 2016
Proposed legislation will accelerate medical innovation

Registration for the 2016 BIO International Convention Now Open

Jan 14 2016

Washington, D.C. (January 14, 2016) – The Biotechnology Innovation Organization (BIO) announced today that

BIO Welcomes Support of Vice President Biden in Fight to Cure Cancer

Jan 12 2016
Washington, D.C. (January 12, 2016) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood released the following statement today regarding Vice President Joe Biden’s “moon shot” initiative to find a cure for cancer.

2016 BIO CEO & Investor Conference Buzz of BIO Winners Announced

Jan 12 2016
Recognizing highly innovative companies in the biotech sector

BIO Announces Appointment of Dan Durham to Lead Health Policy Section

Jan 7 2016
BIO announced today that long-time healthcare policy expert Dan Durham will be joining BIO as Executive Vice President and will lead the organization’s Health Policy Section.

Biotechnology Industry Organization changes name to Biotechnology Innovation Organization

Jan 4 2016
New Name Better Reflects Member's Innovations and Breakthroughs; Organization Will Still Use BIO Name

BIO Expresses Support for Tax Extender Legislation

Dec 16 2015
BIO today welcomed legislation to extend critical tax incentives that are important to biotechnology companies. The legislation would make permanent the important Research & Development Tax Credit.

BIO and PPMD Launch Initiative to Share Best Practices on Patient Preference Studies

Dec 8 2015
BIO and Parent Project Muscular Dystrophy (PPMD) announce the launch of a new initiative designed to share best practices for the development of disease-specific patient preference studies. Through this effort, BIO and PPMD will produce a document outlining key considerations to help guide stakeholders on the development of patient preference studies, which can be used for multiple purposes, including informing the drug development and regulatory processes...

Biotech Leader Provides Testimony Before House Capital Markets Subcommittee

Dec 2 2015
BIO supports legislation to follow up on the success of the JOBS Act